Depression treatment
Can a CBT phone app help stubborn depression?
Open access · cc by · source: Europe PMC
Adding a smartphone CBT program to a medication switch improved depressive symptoms more than switching antidepressants alone.
Study at a glance
- Design
- RCT — Kokoro-app smartphone CBT plus antidepressant switch vs medication change alone
- N
- N=164 · ITT; primary outcome at week 9 in 163/164 (99.4%)
- Population
- Adults in Japan with antidepressant-refractory major depression
- Outcome
- PHQ-9 at week 9
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
At week 9, the CBT app group scored about 2.5 PHQ-9 points lower than controls (SMD 0.40) and were more likely to meet response criteria. Remission and side-effect burden differences were not statistically significant. App engagement was high among those assigned CBT.
Methodology
In Japan, adults with antidepressant-refractory major depression were switched to escitalopram or sertraline and randomized to add a structured smartphone CBT app (Kokoro-app) or medication change alone. The primary outcome was PHQ-9 at week 9 in an intention-to-treat analysis of 164 randomized participants.
Limitations
The trial was relatively short (9 weeks), compared adjunctive app CBT with medication switch rather than face-to-face CBT, and does not prove long-term relapse prevention or effectiveness outside Japanese specialty settings.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Adjunctive digital CBT can move a validated symptom score without proving remission or long-term relapse prevention. Adults with antidepressant-refractory major depression randomised to add a smartphone CBT app scored about 2.5 PHQ-9 points lower at week 9 (SMD 0.40) and were more likely to meet response criteria; remission and side-effect differences were not significant.
Evidence for the claim as stated.
Trials disagree on what a 'positive' result is allowed to be. The orthopaedic telemedicine trial treats staying inside a non-inferiority margin as success, whereas the Facebook walking, Text4Heart, Kokoro-app and MoodGYM trials are powered to show the intervention beating control on a change score. A student who reads only superiority language will misread a successful non-inferiority trial as 'no difference, so it failed.'
Evidence for the claim as stated.
Adjunctive smartphone CBT in antidepressant-refractory major depression used ITT on 164 randomised participants: at week 9 the Kokoro-app arm scored about 2.5 PHQ-9 points lower (SMD 0.40) and was more likely to meet response criteria, while remission and side-effect differences were not significant. Deprexis, in 396 adults recruited online, improved BDI by about 5.4 points (d=0.58) versus delayed treatment. Neither ITT result is a head-to-head against face-to-face CBT or a long-term relapse trial.
Evidence for the claim as stated.
ITT mixed models do not travel with equal credibility across dropout patterns. MoodGYM's 2.5–2.9 point WEMWBS advantage sits on 73.5% versus 26.9% attrition and a wait-list control. Kokoro-app's 2.5-point PHQ-9 contrast had high engagement among those assigned CBT. Same analysis label, very different missing-data threats.
Evidence for the claim as stated.
Repeated-measures RCTs in this set move behaviour or symptoms while the stimulus is on. A 50-day Facebook walking programme increased walking by about 155 min/week (P < .001) with 87.3% retention, but between-group advantages were gone three months after the app ended. Adjunctive Kokoro-app CBT produced about a 2.5-point PHQ-9 advantage at week 9 (SMD 0.40) among 164 randomised participants, without a significant remission difference.
Evidence for the claim as stated.
A mixed model with a randomised control (MoodGYM, Kokoro-app, Facebook walking, Glucose Buddy) answers a different question from a mixed model of change inside one arm (IntelliCare field trial, Fitbit wear). Significant PHQ-9/GAD-7 improvement to 37%/42% below 5, or MVPA doubling from 93.8 to 195.3 min/week, can be expectancy, concurrent care, or the surrounding activity trial. Those papers do not licence the same causal sentence as a 2.5-point randomised PHQ-9 gap.
Evidence for the claim as stated.
Randomised PHQ-9 contrasts in this set are modest-to-moderate and endpoint-specific. Kokoro-app adjunctive CBT in 164 participants with antidepressant-refractory major depression scored about 2.5 PHQ-9 points lower at week 9 (SMD 0.40) with more response but not significantly more remission. Internet CBT for depression in diabetes (91 with baseline data after screening 106) produced Hedges g=0.78 on PHQ-9 and g=0.72 on GAD-7; 66% completed all six lessons, and 51% of iCBT completers with data showed reliable PHQ-9 improvement versus 18% of treatment-as-usual.
Evidence for the claim as stated.
Mean PHQ-9 change, response, remission and 'score <5' are different claims. Kokoro-app's 2.5-point ITT advantage came without a significant remission difference. IntelliCare's uncontrolled 37% below 5 is a threshold count, not a randomised remission rate. iCBT's 51% versus 18% is reliable improvement among completers with data, not the same as g=0.78 on the full ITT sample. Treating those percentages as one 'PHQ-9 worked' statistic collapses the disagreements the papers actually report.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
Trials disagree on what a 'positive' result is allowed to be. The orthopaedic telemedicine trial treats staying inside a non-inferiority margin as success, whereas the Facebook walking, Text4Heart, Kokoro-app and MoodGYM trials are powered to show the intervention beating control on a change score. A student who reads only superiority language will misread a successful non-inferiority trial as 'no difference, so it failed.'
- Supports · Video orthopaedics non-inferior to clinic
- Supports · Facebook team walking RCT
ITT mixed models do not travel with equal credibility across dropout patterns. MoodGYM's 2.5–2.9 point WEMWBS advantage sits on 73.5% versus 26.9% attrition and a wait-list control. Kokoro-app's 2.5-point PHQ-9 contrast had high engagement among those assigned CBT. Same analysis label, very different missing-data threats.
- Supports · MoodGYM improves population wellbeing
A mixed model with a randomised control (MoodGYM, Kokoro-app, Facebook walking, Glucose Buddy) answers a different question from a mixed model of change inside one arm (IntelliCare field trial, Fitbit wear). Significant PHQ-9/GAD-7 improvement to 37%/42% below 5, or MVPA doubling from 93.8 to 195.3 min/week, can be expectancy, concurrent care, or the surrounding activity trial. Those papers do not licence the same causal sentence as a 2.5-point randomised PHQ-9 gap.
- Supports · MoodGYM improves population wellbeing
- Supports · IntelliCare app suite field trial
- Supports · Fitbit wear during an activity trial
Mean PHQ-9 change, response, remission and 'score <5' are different claims. Kokoro-app's 2.5-point ITT advantage came without a significant remission difference. IntelliCare's uncontrolled 37% below 5 is a threshold count, not a randomised remission rate. iCBT's 51% versus 18% is reliable improvement among completers with data, not the same as g=0.78 on the full ITT sample. Treating those percentages as one 'PHQ-9 worked' statistic collapses the disagreements the papers actually report.
- Supports · IntelliCare app suite field trial
- Supports · iCBT for depression in diabetes
Related papers in this topic
Same topic cluster — not a recommendation engine.